Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
F 6.55 -2.89% -0.20
RLAY closed down 1.32 percent on Tuesday, April 16, 2024, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 2
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Doji - Bullish? Reversal -2.89%
Down 3 Days in a Row Weakness -2.89%
Oversold Stochastic Weakness -2.89%
Oversold Stochastic Weakness -4.17%
180 Bearish Setup Bearish Swing Setup -6.90%
MACD Bullish Signal Line Cross Bullish -6.90%
NR7 Range Contraction -6.90%
Narrow Range Bar Range Contraction -6.90%
Stochastic Reached Oversold Weakness -6.90%
Oversold Stochastic Weakness -6.90%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown 2 minutes ago
Fell Below Previous Day's Low 40 minutes ago
Down 2 % 40 minutes ago
Down 1% 40 minutes ago
60 Minute Opening Range Breakout about 24 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Receptors Tyrosine Kinase Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Proto Oncogene Tyrosine Protein Kinase Src Ptpn11

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.32
52 Week Low 5.95
Average Volume 1,189,317
200-Day Moving Average 9.51
50-Day Moving Average 8.76
20-Day Moving Average 7.44
10-Day Moving Average 7.01
Average True Range 0.46
RSI (14) 33.77
ADX 34.79
+DI 12.52
-DI 32.58
Chandelier Exit (Long, 3 ATRs) 7.06
Chandelier Exit (Short, 3 ATRs) 7.99
Upper Bollinger Bands 8.41
Lower Bollinger Band 6.48
Percent B (%b) 0.13
BandWidth 25.84
MACD Line -0.57
MACD Signal Line -0.58
MACD Histogram 0.0073
Fundamentals Value
Market Cap 859.09 Million
Num Shares 127 Million
EPS -2.67
Price-to-Earnings (P/E) Ratio -2.52
Price-to-Sales 46.66
Price-to-Book 1.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.31
Resistance 3 (R3) 7.33 7.17 7.22
Resistance 2 (R2) 7.17 7.02 7.16 7.18
Resistance 1 (R1) 6.95 6.93 7.06 6.93 7.15
Pivot Point 6.79 6.79 6.84 6.78 6.79
Support 1 (S1) 6.57 6.64 6.68 6.55 6.33
Support 2 (S2) 6.41 6.55 6.40 6.30
Support 3 (S3) 6.19 6.41 6.27
Support 4 (S4) 6.17